tpi1a Antibody

What is TPI1/tpi1a and what role does it play in cellular metabolism?

Triosephosphate isomerase 1 (TPI1), also known as tpi1a in zebrafish, is a key glycolytic enzyme that catalyzes the reversible interconversion of dihydroxyacetone phosphate (DHAP) to glyceraldehyde 3-phosphate (GAP) in the glycolytic pathway. It is essential for controlling glycolytic flow and energy production in cells .

TPI1 belongs to the triosephosphate isomerase family and plays a significant role in glucose metabolism. The enzyme is highly conserved across species, from zebrafish to humans, reflecting its fundamental importance in cellular metabolism . Recent research has demonstrated that beyond its canonical metabolic role, TPI1 may have additional functions, including involvement in cancer progression through mechanisms potentially independent of its enzymatic activity .

What applications are tpi1a antibodies validated for in zebrafish research?

The tpi1a antibody designed for zebrafish research has been validated for specific applications including:

The antibody is specifically designed to recognize the tpi1a protein in Danio rerio (zebrafish), having been developed using recombinant zebrafish tpi1a protein as the immunogen . When designing experiments, it's important to note that this antibody is intended for research use only and should not be used for diagnostic or therapeutic procedures .

What are the recommended storage conditions for maintaining tpi1a antibody stability?

For optimal maintenance of tpi1a antibody activity:

• Store at -20°C or -80°C upon receipt

• Avoid repeated freeze-thaw cycles that can degrade antibody quality

• For long-term storage, aliquoting is recommended to minimize freeze-thaw cycles

• Most tpi1a antibodies are supplied in a storage buffer containing preservatives (such as 0.03% Proclin 300) and stabilizers (50% Glycerol in 0.01M PBS, pH 7.4)

Research has shown that antibody stability can be significantly affected by improper storage. Stability studies with other antibodies have demonstrated that repeated freeze-thaw cycles can reduce binding activity, as shown in testing where antibodies were subjected to multiple freeze-thaw cycles and then evaluated in immunoassays .

How do I interpret conflicting results between TPI1 antibody data and other experimental approaches?

Researchers occasionally encounter contradictions between antibody-based results and other experimental methods:

Systematic approach to resolving conflicts:

• Evaluate antibody reliability:

  • Re-examine validation data for the specific antibody used

  • Check antibody batch/lot variation

  • Confirm application-specific validation (e.g., an antibody validated for WB may not work in IHC)

• Consider biological explanations:

  • Post-translational modifications may affect antibody recognition

  • Protein localization changes under different conditions

  • Protein half-life vs. mRNA half-life differences

• Technical investigation:

  • Different sensitivity thresholds between methods

  • Sample preparation differences affecting epitope availability

  • Experimental timing differences (dynamic protein expression)

• Integrative resolution strategies:

  • Use orthogonal approaches for confirmation

  • Employ tagged-protein expression systems as controls

  • Consider mass spectrometry validation for protein identification

Case study approach from literature:
Researchers studying TPI1 in cancer found discrepancies between antibody staining and functional outcomes. They resolved this by demonstrating that "the tumor promoting function of TPI1 is independent of its enzymatic catalytic activity, but dependent on its translocation to cell nucleus" , highlighting how functional data can appear to conflict with expression data until subcellular localization is considered.

What are emerging research areas where tpi1a antibodies could provide novel insights?

Several cutting-edge research areas could benefit from tpi1a antibody applications in zebrafish models:

Emerging research directions:

• Developmental metabolic reprogramming:

  • Track tpi1a expression/localization during different developmental stages

  • Correlate with metabolic shifts during organogenesis

  • Investigate potential non-glycolytic roles during development

• Stress response and disease models:

  • Study tpi1a nuclear translocation under different stress conditions in zebrafish

  • Investigate the role of tpi1a in zebrafish models of neurodegeneration

  • Explore potential therapeutic targets based on tpi1a function

• Evolutionary conservation of non-canonical functions:

  • Compare tpi1a localization and interactome between zebrafish and mammalian models

  • Investigate whether stress-induced translocation is conserved across species

  • Study species-specific differences in tpi1a regulation

These emerging areas represent frontiers where tpi1a antibody research could make significant contributions to understanding both basic biology and disease mechanisms.